Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection

被引:4
|
作者
Martinez-Bonet, M. [1 ,2 ,3 ]
Gonzalez-Serna, A. [1 ,4 ]
Clemente, M. I. [1 ,2 ,3 ]
Moron-Lopez, S. [5 ]
Diaz, L. [1 ,2 ,3 ]
Navarro, M. [6 ]
Puertas, M. C. [5 ]
Leal, M. [4 ]
Ruiz-Mateos, E. [4 ]
Martinez-Picado, J. [5 ,7 ,8 ]
Munoz-Fernandez, M. A. [1 ,2 ,3 ]
机构
[1] IiSGM, Hosp Gen Univ Gregorio Maranon, Sect Immunol, Lab Immuno Mol Biol, Madrid, Spain
[2] Spanish HIV HGM BioBank, Madrid, Spain
[3] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain
[4] Univ Seville, Lab Immunovirol, Clin Unit Infect Dis Microbiol & Prevent Med, Inst Biomed Seville,IBiS,Virgen Rocio Univ Hosp,C, Seville, Spain
[5] Univ Autonoma Barcelona, AIDS Res Inst IrsiCaixa, Inst Invest Ciencies Salut Germans Trias i Pujol, Badalona, Spain
[6] Hosp Gen Univ Gregorio Maranon, Dept Infect Dis Sect, Paediat Serv, Madrid, Spain
[7] Univ Vic Univ Cent Catalunya UVic UCC, Barcelona, Spain
[8] ICREA, Barcelona, Spain
关键词
Adolescents; CCR5((WT/Delta 32)); Human immunodeficiency virus-1; Reservoir size; Young adults; SUPPRESSIVE ANTIRETROVIRAL THERAPY; TO-CHILD TRANSMISSION; DISEASE PROGRESSION; CELLS; CCR5; AGE; INDIVIDUALS; ACTIVATION; INFANTS; CD4(+);
D O I
10.1016/j.cmi.2016.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Several host factors contribute to human immunodeficiency virus (HIV) disease progression in the absence of combination antiretroviral therapy (cART). Among them, the CC-chemokine receptor 5 (CCR5) is known to be the main co-receptor used by HIV-1 to enter target cells during the early stages of an HIV-1 infection. Objective: We evaluated the association of CCR5((WT/Delta 32)) heterozygosity with HIV-1 reservoir size, lymphocyte differentiation, activation and immunosenescence in adolescents and young adults with perinatally acquired HIV infection receiving cART. Methods: CCR5 genotype was analysed in 242 patients with vertically transmitted HIV-1 infection from Paediatric Spanish AIDS Research Network Cohort (coRISpe). Proviral HIV-1 DNA was quantified by digital-droplet PCR, and T-cell phenotype was evaluated by flow cytometry in a subset of 24 patients (ten with CCR5((Delta 32/WT)) genotype and 14 with CCR5((WT/WT)) genotype). Results: Twenty-three patients were heterozygous for the Delta 32 genotype but none was homozygous for the mutated CCR5 allele. We observed no difference in the HIV-1 reservoir size (455 and 578 copies of HIV-1 DNA per million CD4(+) T cells in individuals with CCR5((WT/WT)) and CCR5((Delta 32/WT)) genotypes, respectively; p 0.75) or in the immune activation markers between both genotype groups. However, we found that total HIV-1 DNA in CD4(+) T cells correlated with the percentage of memory CD4(+) T cells: a direct correlation in CCR5((WT/Delta 32)) patients but an inverse correlation in those with the CCR5((WT/WT)) genotype. Conclusions: This finding suggests a differential distribution of the viral reservoir compartment in CCR5((WT/Delta 32)) patients with perinatal HIV infection, which is a characteristic that may affect the design of strategies for reservoir elimination. M. Martinez-Bonet, Clin Microbiol Infect 2017;23:318 (C) 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:318 / 324
页数:7
相关论文
共 50 条
  • [1] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [2] Protective effect of CCR5 Δ32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection
    Sei, S
    Boler, AM
    Nguyen, GT
    Stewart, SK
    Yang, QE
    Edgerly, M
    Wood, LV
    Brouwers, P
    Venzon, DJ
    AIDS, 2001, 15 (11) : 1343 - 1352
  • [3] Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection
    Foster, Caroline
    Fidler, Sarah
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (12) : 1403 - 1416
  • [4] HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study
    Foster, C.
    Kaye, S.
    Smith, C.
    Mackie, N. E.
    JOURNAL OF VIRUS ERADICATION, 2015, 1 (03) : 173 - 178
  • [5] CCR5 antagonists: a therapeutic option in HIV-1 perinatally infected children experiencing virologic failure?
    Frange, Pierre
    Briand, Nelly
    Veber, Florence
    Moshous, Despina
    Avettand-Fenoel, Veronique
    Rouzioux, Christine
    Blanche, Stephane
    Chaix, Marie-Laure
    AIDS, 2012, 26 (13) : 1673 - 1677
  • [6] Distribution of CCR5 Δ32 HIV-1 resistance allele frequency at Zanjan province in Iran
    Farshbaf, Alieh
    Biglari, Alireza
    Faghihzadeh, Soghrat
    Esmaeilzadeh, Abdolreza
    IMMUNOPATHOLOGIA PERSA, 2021, 7 (02):
  • [7] Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
    Mohamed, Hager
    Gurrola, Theodore
    Berman, Rachel
    Collins, Mackenzie
    Sariyer, Ilker K.
    Nonnemacher, Michael R.
    Wigdahl, Brian
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [8] Effect of CCR5-Δ32 Heterozygosity on HIV-1 Susceptibility: A Meta-Analysis
    Liu, SiJie
    Kong, ChuiJin
    Wu, Jie
    Ying, Hao
    Zhu, HuanZhang
    PLOS ONE, 2012, 7 (04):
  • [9] CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
    Samantha J. Westrop
    Graeme Moyle
    Akil Jackson
    Mark Nelson
    Sundhiya Mandalia
    Nesrina Imami
    Molecular Medicine, 2012, 18 : 1240 - 1248
  • [10] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
    Kuemmerle, Tim
    Lehmann, Clara
    Hartmann, Pia
    Wyen, Christoph
    Faetkenheuer, Gerd
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785